Active	Status	Sponsor type	Region	Phase	Filter
8 Active 1 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ADG106 / Adagene
ADIVO Lung, NCT05236608: A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC	Recruiting	1b/2	53	RoW	Nivolumab, Opdivo, ADG106	National University Hospital, Singapore, Adagene Inc, Bristol-Myers Squibb, Singapore Translational Cancer Consortium	Metastatic Non Small Cell Lung Cancer	05/24	05/24
ChiCTR2000041353: The Efficacy and safety Study of Icaritin combined with ADG 106 in the treatment of advanced HCC patient	Recruiting	1/2	20		Treatment of Icaritin soft capsule combined with ADG106 injection	Chinese PLA General Hospital; Chinese PLA General Hospital, Beijing Shenogen Biomedical Co.,Ltd, Adagene (SuZhou) Limited	Liver Cancer
NCT04775680: Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma	Terminated	1/2	25	RoW	ADG106 injection, PD-1 antibody injection	Adagene (Suzhou) Limited	Solid Tumor, Non Hodgkin Lymphoma	02/23	02/23
NCT04645069: ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors	Completed	1/2	58	US, RoW	ADG126 Mono, ADG126-anti PD1, ADG126-ADG106	Adagene Inc	Advanced/Metastatic Solid Tumors	01/24	05/24
NCT05275777: A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer	Active, not recruiting	1/2	66	RoW	ADG106, Doxorubicin, Adriamycin, Cyclophosphamide, Cytophosphane, Paclitaxel, Taxol	National University Hospital, Singapore, Adagene Inc	HER2-negative Breast Cancer, Advanced Solid Tumor	12/27	02/30
ComPACT, NCT05491083: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer	Recruiting	1b	51	RoW	Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II)	National University Hospital, Singapore, Adagene Inc, Merck Sharp & Dohme LLC	Advanced Solid Tumor, Triple Negative Breast Cancer	12/25	12/26
ADG106-1002, NCT03802955: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma	Completed	1	62	RoW	ADG106	Adagene (Suzhou) Limited	Solid Tumor, Non-Hodgkin Lymphoma	11/21	11/21
ADG116-1003, NCT04501276: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients	Active, not recruiting	1	72	US, RoW	ADG116, ADG106, anti PD1 drug	Adagene Inc	Advanced/Metastatic Solid Tumors	01/24	02/25